Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CRDF · as of Sep 30, 2025
Ownership Breakdown
122
Institutional Holders
▼ 1 vs Q2
$52.15M
Total Inst. Value
▼ $38.12M vs Q2
68.37M
Shares Outstanding
freeFloat 97.57%
25.22M
13F Shares Held
▼ 3.44M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CRDF largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.99M | 5.99% | 5.99% | $8.21B | Nov 12, 2025 | ▲ 49.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.59M | 5.39% | 5.39% | $7.39B | Nov 7, 2025 | ▼ 139.4K |
LAURION CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 2.47M | 3.71% | 3.71% | $5.08B | Nov 17, 2025 | ▲ 668.6K |
PFIZER INC biological products, (no diagnostic substances) | 2.41M | 3.63% | 3.63% | $4.97B | Nov 13, 2025 | — held |
BLAIR WILLIAM & CO/IL biological products, (no diagnostic substances) | 2.21M | 3.33% | 3.33% | $4.56B | Nov 12, 2025 | ▼ 310.5K |
ACORN CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 1.96M | 2.95% | 2.95% | $4.04B | Nov 17, 2025 | ▲ 553.3K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.54M | 2.32% | 2.32% | $3.18B | Nov 12, 2025 | ▲ 44.5K |
STATE STREET CORP biological products, (no diagnostic substances) | 1.15M | 1.72% | 1.72% | $2.36B | Nov 14, 2025 | ▲ 19.8K |
UBS GROUP AG biological products, (no diagnostic substances) | 633.0K | 95.15% | 95.15% | $1.30B | Nov 13, 2025 | — held |
FLPUTNAM INVESTMENT MANAGEMENT CO biological products, (no diagnostic substances) | 597.2K | 89.77% | 89.77% | $1.23B | Oct 10, 2025 | ▲ 543.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+3.00M shares3
New Positions
first time holders15
Decreased
−3.92M shares0
Sold Out
fully exitedNet shares change (top 50)
915.5K
+3.00M / −3.92M
Net new holders
+10
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CRDF insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Aggarwal Ajay Chief Operating Officer | Apr 27, 2026 | Award | 400,000 | $1.72 | $688.0K | 400.0K | Form 4 ↗ |
Smeal Tod Chief Scientific Officer | Apr 14, 2026 | Award | 300,000 | $1.63 | $489.0K | 1.28M | Form 4 ↗ |
Muntner Joshua B Chief Financial Officer | Apr 6, 2026 | Award | 486,650 | $1.58 | $768.9K | 487.1K | Form 4 ↗ |
Mohindru Mani Chief Executive Officer | Mar 31, 2026 | Award | 600,000 | $1.62 | $972.0K | 968.8K | Form 4 ↗ |
Lindsay Brigitte Ute Chief Accounting Officer | Feb 13, 2026 | Award | 200,000 | $1.60 | $320.0K | 1.03M | Form 4 ↗ |
Mohindru Mani Interim CEO | Feb 17, 2026 | Award | 200,000 | $1.56 | $312.0K | 368.8K | Form 4 ↗ |
PACE GARY W director | Jul 30, 2025 | Purchase | 15,000 | $2.45 | $36.8K | 1.35M | Form 4 ↗ |
PACE GARY W director | Jul 30, 2025 | Purchase | 275,000 | $2.45 | $673.8K | 1.33M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cardiff Oncology, Inc. (CRDF) is primarily owned by institutional investors, who hold approximately 36.9% of total shares outstanding. Company insiders own approximately 2.43%, while retail and public investors account for the remaining 60.69%.
The largest institutional shareholder of Cardiff Oncology, Inc. is BLACKROCK, INC., holding approximately 3.99 million shares — equal to 5.99% of outstanding shares — as of September 30, 2025.
A total of 122 institutional investors currently hold CRDF stock, with a combined institutional value of approximately $52,147,381 as of the most recent 13F filing period.
Frequently asked questions
CRDF ownershipCardiff Oncology, Inc. (CRDF) is primarily owned by institutional investors, who hold approximately 36.9% of shares. The largest shareholder is BLACKROCK, INC. with a 5.99% stake. Company insiders hold 2.43%. Data sourced from SEC Form 13F as of September 30, 2025.